Targeting a neoantigen derived from a common TP53 mutation

TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at positi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Science
Autors principals: Hsiue, Emily Han-Chung, Wright, Katharine M., Douglass, Jacqueline, Hwang, Michael S., Mog, Brian J., Pearlman, Alexander H., Paul, Suman, DiNapoli, Sarah R., Konig, Maximilian F., Wang, Qing, Schaefer, Annika, Miller, Michelle S., Skora, Andrew D., Azurmendi, P. Aitana, Murphy, Michael B., Liu, Qiang, Watson, Evangeline, Li, Yana, Pardoll, Drew M., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Gabelli, Sandra B., Zhou, Shibin
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8208645/
https://ncbi.nlm.nih.gov/pubmed/33649166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.abc8697
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars